Evidence map›Paper›PMID 37032755›Full record

ArticleTranslational andrology and urology2023

Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis.

Yuanqing Gou, Yongxin Fu, Yadong Li, Chuan Liu

Open access · diamondAbstract read
In one paragraph

Article in Translational andrology and urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuanqing GouDepartment of Urology Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yongxin FuDepartment of Urology Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yadong LiDepartment of Urology Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chuan LiuDepartment of Urology Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022. Methods: The Web of Science Core Collection database was searched using the search terms "renal cancer", "kidney neoplasms", "kidney cancer", and "targeted therapy", and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution. Results: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the Conclusions: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field.

Indexed as

bibliometric analysisrenal cancerTargeted therapyVOSviewer

Identifiers

PMID37032755
PMCPMC10080350
OpenAlexW4361277902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.